Scientists have developed a new vaccine based on the same microRNA technology used in vaccines against coronavirus. It can prevent the recurrence of deadly pancreatic cancer.
Researchers at the Memorial Sloan Kettering Cancer Center in New York have developed a unique vaccine that protects against the recurrence of pancreatic cancer. Preliminary clinical studies have suggested that this personalized vaccine teaches the body not to let the deadly tumor spread again. After the diagnosis of pancreatic cancer is established, no more than 25% of its victims remain alive after a year. Unfortunately, this tumor develops undiagnosed for a long time, because the immune system does not consider tumor cells a threat.
However, a small number of patients still have a good prognosis, since in their case the tumor can be removed. And now American oncologists have discovered that these tumors contain a large number of pathogen-destroying T cells. They conducted a clinical study in 16 patients with pancreatic cancer who received a customized vaccine after surgery.
The vaccine uses a piece of the tumor's genetic code to train cells to produce a protein that activates the immune response. This allows the body to recognize cancer and treat it. T cells destroy the tumor if it comes back. In 8 participants in the experiment, the vaccine activated T-cells to recognize the disease, and after a year and a half they had no signs of cancer. (READ NEXT) 
< p class="article_expert_name" itemprop="name">Memorial Sloan Kettering Cancer Centre
Medicine
Cancer Center, which deals with the treatment and study of cancer in New York, USA. The center was founded in 1884 as the New York Cancer Hospital